may
case
fall
norm
typic
progress
practic
clinician
need
reli
clinic
judgment
use
guidelin
gener
howev
diagnosi
abr
may
made
adult
children
symptom
viral
uri
improv
day
worsen
day
may
follow
sign
symptom
nasal
drainag
nasal
congest
facial
pressurepain
especi
unilater
focus
region
particular
sinu
postnas
drainag
hyposmiaanosmia
fever
cough
fatigu
maxillari
dental
pain
ear
pressureful
physic
examin
provid
limit
inform
diagnosi
abr
sometim
help
plain
film
radiograph
comput
tomographi
ct
magnet
reson
imag
scan
necessari
case
abr
common
bacteri
speci
isol
maxillari
sinus
patient
abr
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
latter
common
children
streptococc
speci
anaerob
bacteria
staphylococcu
aureu
caus
small
percentag
case
increas
preval
penicillin
nonsuscept
resist
drug
class
among
pneumonia
problem
unit
state
penicillinintermedi
penicillinresist
recent
studi
resist
macrolid
trimethoprimsulfamethoxazol
tmpsmx
also
common
pneumonia
preval
isol
h
influenza
approxim
essenti
catarrhali
isol
produc
resist
h
influenza
tmpsmx
also
common
guidelin
appli
adult
children
select
antibiot
therapi
abr
clinician
consid
sever
diseas
rate
progress
diseas
recent
antibiot
exposur
guidelin
divid
patient
abr
two
gener
categori
mild
symptom
receiv
antibiot
within
past
week
mild
diseas
receiv
antibiot
within
past
week
moder
diseas
regardless
recent
antibiot
exposur
differ
sever
diseas
impli
infect
resist
pathogen
rather
terminolog
indic
rel
degre
accept
possibl
treatment
failur
likelihood
spontan
resolut
symptomspati
sever
symptom
less
like
resolv
diseas
spontan
primari
goal
antibiot
therapi
erad
bacteria
site
infect
turn
help
return
sinus
back
health
decreas
durat
symptom
allow
patient
resum
daili
activ
quickli
prevent
sever
complic
mening
brain
abscess
decreas
develop
chronic
diseas
sever
lifethreaten
infect
without
complic
rare
address
guidelin
prior
antibiot
use
major
risk
factor
associ
develop
infect
antimicrobialresist
strain
recent
antimicrobi
exposur
increas
risk
carriag
infect
due
resist
organ
antimicrobi
therapi
base
upon
patient
histori
recent
antibiot
use
panel
guidelin
therefor
stratifi
patient
accord
antibiot
exposur
previou
week
lack
respons
therapi
hour
arbitrari
time
establish
defin
treatment
failur
clinician
monitor
respons
antibiot
therapi
may
includ
instruct
patient
call
offic
clinic
symptom
persist
worsen
next
day
predict
bacteriolog
clinic
efficaci
antibiot
adult
children
determin
accord
mathemat
model
abr
develop
michael
pool
md
phd
base
pathogen
distribut
resolut
rate
without
treatment
vitro
microbiolog
activ
antibiot
place
follow
rel
rank
order
predict
clinic
efficaci
adult
respiratori
fluoroquinolon
gatifloxacin
levofloxacin
moxifloxacin
ceftriaxon
highdos
amoxicillinclavulan
mgday
amoxicillinclavulan
mgday
highdos
amoxicillin
gday
amoxicillin
gday
cefpodoxim
proxetil
cefixim
base
h
influenza
catarrhali
coverag
cefuroxim
axetil
cefdinir
tmpsmx
doxycyclin
clindamycin
base
gramposit
coverag
azithromycin
clarithromycin
erythromycin
telithromycin
cefaclor
loracarbef
predict
spontan
resolut
rate
patient
clinic
diagnosi
abr
antibiot
place
follow
rel
rank
order
predict
clinic
efficaci
children
abr
ceftriaxon
highdos
amoxicillinclavulan
mg
per
kg
per
day
amoxicillinclavulan
mg
per
kg
per
day
highdos
amoxicillin
mgkg
per
day
amoxicillin
mgkg
per
day
cefpodoxim
proxetil
cefixim
base
h
influenza
catarrhali
coverag
cefuroxim
axetil
cefdinir
tmpsmx
clindamycin
base
gramposit
coverag
cefprozil
azithromycin
clarithromycin
erythromycin
cefaclor
loracarbef
predict
spontan
resolut
rate
untreat
children
presum
diagnosi
abr
recommend
initi
therapi
adult
patient
mild
diseas
receiv
antibiot
previou
week
includ
follow
choic
amoxicillinclavulan
mg
per
day
amoxicillin
gday
cefpodoxim
proxetil
cefuroxim
axetil
cefdinir
tmpsmx
doxycyclin
azithromycin
clarithromycin
erythromycin
telithromycin
may
consid
patient
allergi
bacteriolog
failur
rate
possibl
failur
respond
antimicrobi
therapi
hour
prompt
either
switch
altern
antimicrobi
therapi
reevalu
patient
see
tabl
chang
antibiot
therapi
made
clinician
consid
limit
coverag
initi
agent
recommend
initi
therapi
adult
mild
diseas
receiv
antibiot
previou
week
adult
moder
diseas
includ
follow
choic
respiratori
fluoroquinolon
eg
gatifloxacin
levofloxacin
moxifloxacin
highdos
amoxicillinclavulan
mg
per
day
widespread
use
respiratori
fluoroquinolon
patient
milder
diseas
may
promot
resist
wide
spectrum
organ
class
agent
ceftriaxon
parenter
gday
day
combin
therapi
adequ
gramposit
neg
coverag
may
also
consid
exampl
appropri
regimen
combin
therapi
includ
highdos
amoxicillin
clindamycin
plu
cefixim
highdos
amoxicillin
clindamycin
plu
rifampin
clinic
effect
ceftriaxon
combin
abr
unproven
panel
consid
reason
therapeut
option
base
spectrum
activ
agent
data
extrapol
acut
otiti
media
studi
rifampin
use
monotherapi
casual
longer
day
resist
quickli
develop
agent
rifampin
also
wellknown
induc
sever
cytochrom
isoenzym
therefor
high
potenti
drug
interact
failur
patient
respond
antimicrobi
therapi
hour
therapi
prompt
either
switch
altern
antimicrobi
therapi
reevalu
patient
see
tabl
chang
antibiot
therapi
made
clinician
consid
limit
coverag
initi
agent
patient
receiv
effect
antibiot
therapi
continu
symptomat
may
need
evalu
ct
scan
fiberopt
endoscopi
sinu
aspir
cultur
may
necessari
recommend
initi
therapi
children
mild
diseas
receiv
antibiot
previou
week
includ
follow
highdos
amoxicillinclavulan
mg
per
kg
per
day
amoxicillin
mgkg
per
day
cefpodoxim
proxetil
cefuroxim
axetil
cefdinir
tmpsmx
azithromycin
clarithromycin
erythromycin
recommend
patient
histori
immedi
type
hypersensit
reaction
antibiot
limit
effect
major
pathogen
abr
bacteri
failur
possibl
clinician
differenti
immedi
hypersensit
reaction
less
danger
side
effect
children
immedi
hypersensit
reaction
may
need
desensit
sinu
cultur
ancillari
procedur
studi
children
type
reaction
side
effect
may
toler
one
specif
anoth
failur
respond
antimicrobi
therapi
hour
prompt
either
switch
altern
antimicrobi
therapi
reevalu
patient
see
tabl
chang
antibiot
therapi
made
clinician
consid
limit
coverag
initi
agent
recommend
initi
therapi
children
mild
diseas
receiv
antibiot
previou
week
children
moder
diseas
highdos
amoxicillinclavulan
mg
per
kg
per
day
cefpodoxim
proxetil
cefuroxim
axetil
cefdinir
may
use
penicillin
allergi
eg
penicillin
rash
instanc
cefdinir
prefer
high
patient
accept
tmpsmx
azithromycin
clarithromycin
erythromycin
recommend
patient
allerg
provid
optim
coverag
clindamycin
appropri
pneumonia
identifi
pathogen
ceftriaxon
parenter
mgkg
per
day
day
combin
therapi
adequ
gramposit
neg
coverag
may
also
consid
exampl
appropri
regimen
combin
therapi
includ
highdos
amoxicillin
clindamycin
plu
cefixim
highdos
amoxicillin
clindamycin
plu
rifampin
clinic
effect
ceftriaxon
combin
abr
unproven
panel
consid
reason
therapeut
option
base
spectrum
activ
data
extrapol
acut
otiti
media
studi
rifampin
use
monotherapi
casual
longer
day
resist
quickli
develop
agent
failur
respond
antimicrobi
therapi
hour
therapi
prompt
either
switch
altern
antimicrobi
therapi
reevalu
patient
see
tabl
chang
antibiot
therapi
made
clinician
consid
limit
coverag
initi
agent
patient
receiv
effect
antibiot
therapi
continu
symptomat
may
need
evalu
ct
scan
fiberopt
endoscopi
sinu
aspir
cultur
may
necessari
sinu
allergi
health
partnership
conjoint
group
initi
sponsor
american
academi
otolaryngolog
head
neck
surgeri
american
academi
otolaryng
allergi
american
rhinolog
societi
consult
repres
center
diseas
control
prevent
cdc
food
drug
administr
fda
individu
field
infecti
diseas
pediatr
infecti
diseas
microbiolog
pharmaci
develop
guidelin
educ
tool
healthcar
provid
involv
manag
patient
acut
bacteri
rhinosinus
abr
guidelin
publish
wide
accept
howev
recent
data
sinc
time
public
approv
new
antimicrobi
agentsclass
may
impact
util
recommend
result
guidelin
updat
includ
recent
inform
manag
principl
antimicrobi
suscept
pattern
therapeut
option
sever
issu
attempt
address
process
write
document
diagnosi
bacteri
sinus
made
frequentlypati
viral
ill
day
durat
inappropri
label
bacteri
diseas
therefor
patient
prescrib
antibiot
ineffect
viral
pathogen
also
risk
lead
increas
resist
among
respiratori
tract
pathogen
particularli
streptococcu
pneumonia
document
reader
taken
stepwis
approach
complex
diseas
burden
pathophysiolog
definit
abr
review
along
attribut
limit
variou
diagnost
modal
also
includ
guidelin
critic
review
antimicrobi
treatment
option
abr
clinic
trial
conduct
era
widespread
antimicrobi
resist
begin
provid
suffici
evid
use
basi
recommend
treatment
option
gener
suffici
power
object
use
lieu
evid
sever
factor
may
use
clinician
select
therapi
individu
patient
factor
includ
pathogen
distribut
abr
pharmacokinet
pharmacodynam
principl
mechan
antimicrobi
resist
data
vitro
surveil
studi
mani
factor
incorpor
mathemat
model
use
object
compar
variou
antimicrobi
option
abr
hope
guidelin
continu
wellaccept
part
nation
intern
effort
coordin
cdc
fda
aim
educ
healthcar
provid
patient
judici
antimicrobi
use
avoid
abus
overus
valuabl
agent
misus
antibiot
replac
spend
time
talk
examin
patient
teach
patient
andor
famili
member
differ
viral
bacteri
infect
reli
pharmaceut
industri
continu
develop
new
drug
organ
becom
resist
rather
must
decreas
unnecessari
antimicrobi
use
mean
reduc
spread
resist
believ
research
necessari
order
develop
better
method
diagnos
abr
explor
clinic
applic
antibiot
recommend
present
document
monitor
antimicrobi
resist
pattern
among
respiratori
tract
pathogensespeci
pneumonia
haemophilu
influenza
year
unit
state
children
adult
experi
averag
acut
viral
respiratori
ill
respect
patient
actual
comput
tomograph
ct
scan
evid
paranas
sinu
involv
ie
viral
rhinosinus
vr
secondari
bacteri
infect
also
refer
abr
complic
small
number
viral
infect
posit
bacteri
cultur
obtain
roughli
vr
episod
approxim
million
case
abr
would
therefor
expect
base
billion
viral
respiratori
ill
occur
year
sinus
account
pediatr
adult
antibiot
prescript
respect
written
addit
public
health
implic
rhinosinus
consider
econom
impact
recent
estim
suggest
expenditur
attribut
abr
total
approxim
billion
year
unit
state
approxim
million
spent
antibiot
prescript
acut
sinus
differenti
bacteri
viral
rhinosinus
often
challeng
clinic
featur
two
diseas
similar
common
imag
modal
suffici
sensit
specif
result
clinician
often
overtreat
uncompl
rhinosinus
readili
prescrib
antibiot
major
patient
sign
symptom
vr
eg
headach
facial
pain
nasal
congest
rhinorrhea
fever
recent
report
medic
literatur
suggest
primari
care
physician
prescrib
antibiot
patient
clinic
suspect
rhinosinus
practic
treat
uncompl
vr
antibiot
two
fundament
limit
first
secondari
bacteri
infect
complic
rel
small
proport
case
second
excess
antibiot
use
associ
consequ
individu
societi
whole
total
number
antibiot
prescript
increas
throughout
antimicrobi
resist
among
respiratori
tract
pathogen
emerg
signific
public
health
issu
excess
antibiot
use
strongli
associ
develop
spread
bacteri
drug
resist
recent
strategi
promot
prudent
ration
antimicrobi
use
implement
past
sever
year
million
fewer
antibiot
prescript
ambulatori
care
set
compar
reduct
substanti
reduct
antimicrobi
prescrib
occur
respiratori
tract
infect
among
children
year
age
howev
signific
chang
populationbas
antibiot
prescrib
rate
sinus
among
children
rhinosinus
two
featur
antibiot
prescrib
particular
concern
first
frequent
treatment
uncompl
vr
antimicrobi
second
select
antimicrobi
agent
without
document
efficaci
longer
effect
due
develop
resist
continu
goal
panel
develop
guidelin
judici
use
antibiot
treatment
abr
american
academi
otolaryngolog
develop
work
definit
sinus
clarifi
commun
among
healthcar
provid
research
sinus
gener
preced
rhiniti
rare
occur
without
concurr
rhiniti
therefor
sinus
best
describ
rhinosinus
term
acut
subacut
recurr
acut
chronic
rhinosinus
also
review
defin
terminolog
subsequ
adopt
agenc
health
care
polici
research
develop
document
diagnosi
treatment
acut
bacteri
rhinosinus
abr
often
preced
viral
upper
respiratori
tract
infect
uri
allergi
trauma
environment
factor
lead
inflamm
nose
paranas
sinus
may
also
predispos
individu
develop
abr
approxim
common
cold
caus
human
rhinoviru
virus
caus
rhinosinus
includ
coronaviru
influenza
b
virus
parainfluenza
viru
respiratori
syncyti
viru
adenoviru
enteroviru
viral
infect
occur
earli
fall
earli
spring
incid
sinus
follow
similar
pattern
human
rhinoviru
coronaviru
caus
major
epitheli
damag
influenza
viru
adenoviru
caus
signific
damag
nasal
epithelium
human
rhinoviru
exampl
enter
via
nose
lacrim
duct
attach
receptor
epitheli
cell
posterior
nasopharynx
upregul
product
histamin
bradykinin
variou
cytokin
includ
tumor
necrosi
leukotrien
virus
also
substanti
suppress
effect
neutrophil
macrophag
lymphocyt
function
effect
neutrophil
function
includ
diminish
adher
chemotact
phagocyt
oxid
secretori
bactericid
function
virus
also
suppress
macrophag
lymphocyt
function
result
patient
viral
uri
gener
vulner
secondari
overgrowth
subsequ
bacteri
infect
pathogen
resid
nasopharynx
pneumonia
h
influenza
anim
model
nontyp
h
influenza
adher
respiratori
epithelium
studi
cotton
rat
respiratori
syncyti
viru
rsv
infect
colon
nontyp
h
influenza
increas
maximum
within
day
rsv
infect
compar
rsv
neg
control
declin
subsequ
day
system
immun
nontyp
h
influenza
measur
iggspecif
antibodi
outer
membran
complex
bactericid
antibodi
influenc
colon
data
suggest
colon
nontyp
h
influenza
significantli
affect
concurr
infect
rsv
howev
site
bacteri
attach
known
mechan
attach
involv
upregul
express
epitheli
cell
surfac
receptor
includ
pafr
subsequ
activ
inflammatori
pathway
parasympathet
nervou
system
gener
symptom
rhinosinus
fever
myalgia
pharyng
frequent
associ
viral
uri
tend
resolv
day
wherea
nasal
congest
cough
may
persist
second
third
week
figur
fever
alon
day
suggest
abr
caus
secondari
bacteri
invas
sinus
unknown
combin
factor
nose
blow
localsystem
immun
virul
viru
colon
nasopharynx
potenti
bacteri
pathogen
eg
pneumonia
variou
environment
factor
may
lead
condit
conduc
bacteri
entri
growth
sinus
children
experi
averag
viral
uri
per
year
potenti
inappropri
antibiot
use
high
popul
mean
durat
viral
uri
rang
day
children
home
care
day
children
day
care
upper
respiratori
tract
symptom
may
howev
last
day
approxim
children
home
care
children
day
care
case
children
day
care
like
protract
respiratori
symptom
patient
common
cold
usual
report
combin
follow
symptom
sneez
rhinorrhea
nasal
congest
hyposmia
anosmia
facial
pressur
postnas
drip
sore
throat
cough
ear
full
fever
myalgia
contrari
popular
belief
chang
color
characterist
nasal
discharg
specif
sign
bacteri
infect
day
viral
infect
mucopurul
nasal
secret
may
occur
due
influx
neutrophil
recent
studi
clinic
sign
symptom
significantli
associ
multivari
model
presenc
bacteria
includ
color
nasal
discharg
facial
pain
radiolog
determin
maxillari
sinus
complet
opac
airfluid
level
mucos
thicken
mm
model
sensit
specif
therefor
could
use
either
screen
tool
diagnost
criterion
bacteri
rhinosinus
author
studi
conclud
sign
symptom
acut
rhinosinus
patient
mildtomoder
clinic
present
poor
predictor
presenc
bacteria
studi
gwaltney
et
al
n
adult
acut
onset
uri
symptom
demonstr
inflamm
within
nose
viscou
secret
sometim
air
bubbl
sinus
ct
scan
week
without
antibiot
therapi
repeat
ct
scan
subject
reveal
show
either
disappear
mark
improv
previous
identifi
abnorm
point
viral
uri
becom
superinfect
pathogen
bacteria
may
determin
repeat
sinu
aspir
studi
sinu
aspir
studi
adult
demonstr
signific
bacteri
growth
approxim
patient
uri
symptom
day
durat
symptom
beyond
day
moder
sensit
predictor
abr
rel
nonspecif
durat
symptom
reliabl
distinguish
prolong
viral
infect
abr
individu
case
may
fall
norm
typic
progress
specif
find
suggest
bacteri
infect
fever
facial
erythema
swell
sever
pain
therefor
clinician
need
reli
clinic
judgment
use
guidelin
gener
diagnosi
abr
may
made
adult
children
viral
uri
resolv
day
worsen
day
accompani
follow
sign
symptom
nasal
drainag
nasal
congest
facial
pressurepain
especi
unilater
focus
region
particular
sinu
postnas
drainag
hyposmia
anosmia
fever
cough
fatigu
maxillari
dental
pain
ear
pressureful
tabl
physic
examin
provid
limit
inform
diagnosi
abr
sever
studi
evalu
whether
certain
sign
symptom
specif
bacteri
infect
howev
studi
methodolog
limit
sinu
aspir
use
document
presenc
absenc
bacteri
infect
unlik
acut
otiti
media
tympan
membran
middl
ear
space
readili
avail
direct
sneez
sore
throat
cough
rhinorrhea
common
persist
signific
proport
patient
persist
last
two
symptom
entir
consist
uncompl
rhinoviru
infect
examin
paranas
sinus
hidden
within
skull
anterior
rhinoscopi
without
topic
decongest
allow
examin
mucosa
inferior
turbin
secret
within
anterior
nose
orient
nasal
septum
fiberopt
endoscopi
allow
visual
middl
meatu
direct
cultur
purul
region
may
correl
cultur
maxillari
sinu
aspir
recent
review
literatur
benning
et
al
report
concord
cultur
materi
obtain
endoscop
guid
middl
meatal
swab
maxillari
sinu
punctur
studi
howev
limit
small
sampl
size
therefor
inadequ
make
recommend
regard
role
endoscop
guid
middl
meatal
cultur
formal
method
identifi
pathogen
abr
time
prospect
studi
current
underway
better
answer
question
diagnost
modal
includ
transillumin
ultrasound
radiolog
imag
transillumin
reproduc
rate
assess
diseas
within
maxillari
sinus
frontal
sinus
respect
differenti
bacteri
viral
infect
bmode
ultrasound
replac
amod
ultrasound
diagnosi
diseas
within
paranas
sinus
howev
maxillari
sinu
adequ
assess
bmode
ultrasound
limit
util
studi
correl
ct
scan
bmode
ultrasound
find
demonstr
sensit
roughli
maxillari
sinus
frontal
sinus
ethmoid
compar
clinic
evalu
sensit
bmode
ultrasound
specif
ultrasound
techniquesensit
may
mark
variat
reliabl
inform
provid
ultrasound
distinguish
viral
bacteri
rhinosinus
plain
film
radiograph
primarili
reveal
patholog
find
maxillari
frontal
sinus
wherea
ethmoid
poorli
visual
use
imag
techniqu
addit
plain
radiograph
imprecis
determin
extent
diseas
metaanalysi
six
studi
demonstr
posit
plain
film
radiograph
moder
sensit
specif
compar
maxillari
sinu
punctur
neg
radiograph
diagnost
valu
either
neg
clinic
examin
ultrasound
ct
scan
clearli
detect
abnorm
within
sinus
howev
previous
note
abnorm
frequent
found
ct
scan
patient
viral
respiratori
diseas
magnet
reson
imag
mri
without
expos
patient
ioniz
radiat
distinctli
reveal
mucos
thicken
fluid
within
paranas
sinus
patient
maxillari
sinus
serial
mri
scan
demonstr
mucos
thicken
persist
week
signific
mucos
chang
seen
ct
mri
may
therefor
persist
significantli
beyond
microbiolog
resolut
bacteri
viral
diseas
ct
mri
scan
recommend
routin
manag
abr
may
help
guid
manag
complex
case
punctur
maxillari
sinu
canin
fossa
inferior
meatu
provid
materi
may
cultur
identifi
bacteri
isol
technic
expertis
requir
minim
complic
procedur
somewhat
uncomfort
patient
maxillari
sinu
punctur
routin
use
case
suspect
abr
usual
reserv
research
set
patient
complic
infect
novel
techniqueseri
sinu
aspir
samplingdevis
anon
ambros
jone
et
al
involv
place
indwel
cathet
maxillari
sinu
techniqu
pro
primari
reason
recommend
antibiot
therapi
abr
withhold
benefit
treatment
unnecessarili
expos
patient
unreason
morbid
particularli
sever
symptom
howev
routin
use
antimicrobi
therapi
patient
experi
mild
sinu
symptom
short
durat
indic
selflimit
viral
rhinosinus
gener
reason
option
risk
associ
promot
resist
unfortun
case
straightforward
decis
whetherand
whento
initi
antimicrobi
therapi
individu
patient
sign
symptom
consist
abr
often
requir
consider
potenti
risk
benefit
treatment
exampl
subset
patient
may
experi
prolong
moder
rel
sever
symptom
attribut
host
factor
eg
immun
respons
anatom
abnorm
rather
bacteri
infect
patient
benefit
initi
earlier
cours
antimicrobi
therapi
might
appropri
primari
goal
antibiot
therapi
abr
erad
bacteri
pathogen
site
infect
help
decreas
durat
symptom
allow
patient
resum
daili
activ
quickli
return
sinus
back
health
prevent
sever
complic
eg
mening
brain
abscess
decreas
likelihood
develop
chronic
diseas
sever
lifethreaten
infect
without
complic
rare
address
guidelin
clinic
trial
conduct
era
widespread
antimicrobi
resist
begin
provid
evid
use
basi
recommend
specif
antimicrobi
treatment
option
gener
suffici
power
lieu
adequ
evid
sever
factor
may
help
clinician
select
therapi
individu
patient
factor
includ
pathogen
distribut
abr
pharmacokinet
pharmacodynam
principl
antimicrobi
activ
mechan
antimicrobi
resist
data
vitro
surveil
studi
factor
includ
symptom
sever
likelihood
infect
resist
pathogen
likelihood
spontan
resolut
base
infect
pathogen
includ
methodolog
use
panel
object
evalu
variou
antimicrobi
option
abr
factor
discuss
detail
bacteria
broadli
classifi
group
base
cellwal
composit
morpholog
characterist
metabol
requir
cell
wall
import
determin
inher
suscept
resist
bacterium
mani
antimicrobi
agent
consist
primarili
protein
lipid
peptidoglycan
layer
peptidoglycan
layer
compos
oligosaccharid
chain
crosslink
short
peptid
serv
major
structur
compon
maintain
cellwal
integr
although
gramposit
gramneg
bacteria
share
mani
common
structur
element
cell
wall
organ
content
element
vari
two
bacteri
class
figur
cell
wall
gramposit
bacteria
consist
almost
entir
thick
peptidoglycan
layer
fuse
outsid
cytoplasm
membran
gramneg
bacteria
howev
cell
wall
compos
hydrophob
lipopolysaccharid
capsul
surround
lipoproteinphospholipid
membran
contain
small
channel
call
porin
thin
peptidoglycan
layer
lie
outer
membran
inner
cytoplasm
membran
two
biolog
layer
separ
periplasm
space
space
import
site
degrad
antibiot
druginactiv
enzym
gramneg
bacteria
penicillinbind
protein
pbp
enzym
essenti
cellwal
synthesi
locat
cytoplasm
membran
pbp
found
gramneg
posit
organ
alter
pbp
decreas
affin
identifi
varieti
organ
common
bacteri
isol
recov
maxillari
sinus
patient
abr
pneumonia
h
influenza
streptococc
speci
moraxella
catarrhali
review
sinu
aspir
studi
perform
adult
abr
suggest
pneumonia
isol
approxim
h
influenza
catarrhali
aspir
figur
children
abr
pneumonia
isol
approxim
h
influenza
catarrhali
recov
aspir
streptococcu
pyogen
anaerob
account
figur
bacteri
isol
found
patient
abr
includ
staphylococcu
aureu
anaerob
start
soon
birth
nasopharynx
colon
flora
viridan
streptococci
corynebacterium
speci
neisseria
speci
anaerob
colon
respiratori
pathogen
occur
intermitt
discuss
month
age
children
colon
least
one
three
major
respiratori
pathogen
pneumonia
h
influenza
catarrhali
pneumococc
strain
persist
nasopharynx
month
point
preval
survey
demonstr
mani
two
third
children
nasopharyng
carriag
pneumococci
children
colon
pneumonia
year
age
frequent
serotypesserogroup
colon
infant
pneumococci
also
high
frequenc
genet
recombin
strain
carri
nasopharynx
may
chang
serotyp
strain
nontyp
h
influenza
also
sequenti
colon
nasopharynx
process
start
infanc
year
age
children
colon
strain
carri
month
mean
month
product
h
influenzaespecif
iga
result
erad
carriag
strain
follow
acquisit
new
strain
differ
surfac
protein
case
pneumonia
h
influenza
catarrhali
colon
nasopharynx
earli
childhood
children
colon
year
age
child
sequenti
colon
differ
strain
catarrhali
otitispron
children
frequent
colon
otherwis
healthi
children
colon
respiratori
pathogen
increas
consider
winter
period
viral
uri
often
result
organ
caus
bacteri
otiti
media
sinus
pelton
et
al
recent
report
pneumonia
recov
approxim
nasopharyng
cultur
perform
healthi
children
versu
cultur
children
present
acut
otiti
media
aom
studi
bernstein
et
al
suggest
toandfro
exchang
organ
nasopharynx
later
nasal
wall
bacteri
pathogen
isol
adenoid
later
wall
nose
children
undergo
adenoidectomi
molecular
type
pair
nontyp
h
influenza
pneumonia
catarrhali
reveal
pair
ident
strain
present
site
simultan
addit
administr
antimicrobi
increas
carriag
antimicrobialresist
strain
bacteri
pathogen
adult
also
colon
nasopharynx
durat
carriag
shorter
children
recent
studi
demonstr
one
primari
respiratori
pathogen
recov
nasopharynx
approxim
adult
pneumococci
gramposit
catalaseneg
facult
anaerob
spheric
bacteria
typic
seen
pair
chain
nutrit
fastidi
requir
complex
media
contain
blood
serum
growth
growth
often
enhanc
carbon
dioxideenrich
atmospher
pneumonia
belong
group
streptococci
distinguish
viridan
group
occur
pair
requir
carbon
dioxid
primari
isol
autolyz
presenc
bile
salt
bile
solubl
optochin
inhibit
optochincontain
disk
pneumococci
usual
encapsul
capsular
polysaccharid
use
serolog
classif
antigen
distinct
capsular
serotyp
distinct
serogroup
serotyp
common
antigen
group
togeth
serogroup
account
design
exampl
serogroup
incid
invas
pneumococc
diseas
vari
serotyp
likelihood
infect
given
serotyp
larg
depend
virul
factor
express
bacteria
pneumolysin
polysaccharid
capsul
two
wide
known
virul
factor
pneumonia
infect
caus
serotyp
serogroup
highest
children
caus
serotyp
highest
adult
serotyp
serogroup
tend
caus
diseas
similar
frequenc
age
group
found
serogroup
account
infect
seven
serotyp
order
decreas
frequenc
account
isol
blood
cerebrospin
fluid
middl
ear
sourc
children
unit
state
present
conjug
pneumococc
vaccin
current
avail
unit
state
antimicrobi
resist
observ
primarili
serotyp
serotyp
frequent
colon
children
expos
antimicrobi
agent
commonli
like
develop
resist
serotyp
rare
acquir
antibioticresist
gene
incid
invas
pneumococc
infect
depend
time
year
furthermor
incid
infect
caus
resist
strain
also
may
increas
winter
month
monia
resist
result
follow
stepwis
alter
pbp
lead
decreas
bind
affin
vari
degre
resist
penicillin
develop
chang
occur
multipl
pbp
alter
affin
six
known
pbp
alter
often
associ
resist
penicillin
penicillin
minimum
inhibitori
concentr
mic
rang
gml
gml
compar
gml
suscept
strain
macrolid
resist
result
primarili
alter
ribosom
bind
site
due
ribosom
methylas
express
efflux
mechan
two
import
gene
respons
macrolideresist
strain
commonli
encount
clinic
set
erm
gene
code
ribosom
methylas
mef
gene
code
macrolidespecif
cell
membranebas
efflux
mechan
efflux
mechan
confer
rel
moder
degre
resist
compar
high
level
resist
seen
strain
alter
ribosom
bind
site
efflux
mechan
gener
common
unit
state
rel
uncommon
part
world
recent
mechan
macrolid
resist
identifi
could
explain
known
resist
determin
novel
mechan
macrolid
resist
involv
mutat
gene
encod
ribosom
protein
ribosom
rna
rrna
mutat
gene
rrna
result
increas
macrolid
mic
howev
effect
variabl
mic
rang
gml
gml
mutat
gene
gener
confer
highlevel
resist
mic
gml
otolaryngologyhead
neck
surgeri
volum
number
sinu
allergi
health
partnership
isol
pneumonia
express
mutant
gene
rare
identifi
sever
surveil
studi
sever
recent
report
macrolid
treatment
failur
result
develop
mutat
therapi
macrolid
ribosom
methylas
also
confer
crossresist
clindamycin
macrolid
usag
particularli
azithromycin
associ
recent
increas
pneumonia
resist
macrolid
unit
state
fluoroquinolon
resist
result
follow
mutat
target
bind
site
agent
dna
gyras
topoisomeras
iv
rather
requir
acquisit
foreign
gene
mutat
parc
gene
encod
topoisomeras
iv
gyra
gene
encod
gyr
subunit
dna
gyras
result
lowlevel
quinolon
resist
mutat
gene
result
express
highlevel
quinolon
resist
although
crossresist
commonli
occur
among
fluoroquinolon
newest
agent
often
remain
activ
strain
becom
resist
older
agent
fluoroquinolon
efflux
mechan
pmra
also
describ
pneumonia
resist
trimethoprim
sulfonamid
also
primarili
result
mutat
target
bind
site
agent
dihydroptero
synthas
dihydrofol
reductas
organ
belong
genu
haemophilu
consist
small
pleomorph
facult
anaerob
gramneg
bacilli
speci
complex
nutrit
requir
growth
enhanc
carbon
dioxideenrich
atmospher
h
influenza
character
requir
hemin
x
factor
nad
v
factor
strain
h
influenza
may
either
encapsul
unencapsul
encapsul
strain
includ
six
serotyp
serotyp
f
howev
nontyp
strain
typic
caus
uri
otiti
media
sinus
acut
exacerb
chronic
bronchiti
accordingli
occurr
infect
affect
use
type
b
vaccin
enza
primari
mechan
resist
product
hydrolyz
amid
bond
ring
thu
inactiv
antibiot
overcom
effect
resist
less
suscept
hydrolysi
specif
inhibitor
develop
thirdgener
cephalosporin
eg
ceftriaxon
cefixim
stabl
presenc
wherea
clavulan
acid
broadspectrum
irrevers
inhibitor
clavulan
acid
destroy
process
inhibit
often
describ
suicid
inhibitor
combin
inhibitor
eg
amoxicillinclavulan
acid
often
use
treatment
mani
bacteria
includ
h
influenza
catarrhali
inhibitor
includ
tazobactam
sulbactam
import
note
inhibitor
serv
increas
amount
activ
compound
target
site
exert
activ
otherwis
suscept
bacteria
therefor
bacteria
inher
suscept
absenc
addit
inhibitor
make
organ
suscept
alter
pbp
also
report
occasion
among
strain
h
influenza
strain
refer
ampicillinresist
blnar
resist
among
blnar
strain
attribut
alter
pbp
gramneg
organ
multipl
efflux
pump
remov
wast
foreign
materi
one
efflux
pump
h
influenza
chromosom
mediat
via
acrab
gene
macrolid
azalid
substrat
pump
result
agent
intrins
poor
activ
h
influenza
speci
consist
aerob
oxidaseposit
gramneg
diplococci
much
less
fastidi
growth
requir
either
pneumococci
haemophilu
speci
grow
simpl
media
without
blood
serum
primari
mechan
resist
express
catarrhali
produc
tion
howev
produc
catarrhali
differ
produc
h
influenza
result
agent
eg
cefpodoxim
proxetil
cefuroxim
axetil
less
activ
catarrhali
h
influenza
see
tabl
catarrhali
also
intrins
resist
trimethoprim
preval
antimicrobi
resist
among
isol
pneumonia
isol
pneumonia
penicillin
mic
gml
defin
penicillinsuscept
wherea
penicillinintermedi
strain
penicillin
mic
gml
penicillinresist
isol
pneumonia
penicillin
mic
gml
latter
two
group
often
refer
penicillinnonsuscept
clinic
signific
vari
differ
discuss
drugresist
pneumonia
drsp
connot
strain
penicillin
mic
gml
andor
resist
class
antibiot
multidrugresist
pneumonia
defin
organ
resist
three
class
antibiot
increas
preval
isol
pneumonia
penicillin
nonsuscept
concern
unit
state
figur
late
earli
penicillinnonsuscept
pneumonia
becam
major
concern
unit
state
alexand
project
worldwid
surveil
studi
collect
respiratori
tract
isol
communitybas
physician
util
pkpd
suscept
breakpoint
evalu
vitro
activ
variou
antimicrobi
agent
recent
data
us
compon
alexand
project
demonstr
isol
penicillinintermedi
penicillinresist
preval
penicillinnonsuscept
appear
peak
decreas
resist
antimicrobi
class
also
decreas
trend
may
attribut
sever
factor
includ
widespread
use
pneumococc
conjug
vaccin
children
sinc
well
less
overal
antimicrobi
use
overal
us
preval
resist
trimethoprimsulfamethoxazol
tmpsmx
macrolid
doxycyclin
clindamycin
respect
typic
resist
class
antimicrobi
higher
among
penicillinnonsuscept
isol
figur
respiratori
fluoroquinolon
ie
preval
isol
h
influenza
vari
slightli
accord
particular
studi
rang
figur
howev
essenti
h
influenza
isol
suscept
highdos
amoxicillinclavulan
cefixim
blnar
strain
h
influenza
rare
unit
state
preval
countri
eg
japan
base
pkpd
suscept
breakpoint
approxim
h
influenza
isol
suscept
erythromycin
clarithromycin
azithromycin
respect
approxim
recent
us
h
influenza
isol
resist
tmpsmx
data
us
compon
alexand
project
demonstr
catarrhali
isol
produc
extens
use
antibiot
may
associ
develop
spread
resist
microorgan
nasopharyng
carriag
resist
isol
pneumonia
relat
recent
antimicrobi
use
well
live
geograph
region
high
volum
antibiot
use
children
exposur
young
children
preval
isol
catarrhali
found
increas
proport
cephalosporin
use
finland
consumpt
erythromycin
relat
increas
preval
erythromycinresist
group
streptococci
furthermor
steadi
statist
signific
declin
macrolideresist
group
streptococci
occur
reduc
use
macrolid
antibiot
year
reinforc
rational
judici
use
antibiot
numer
method
may
util
assess
vitro
activ
antibiot
test
minim
inhibitori
concentr
mic
minim
bactericid
concentr
mbc
timekil
test
valid
method
assess
antimicrobi
activ
howev
import
understand
use
limit
test
antimicrobi
activ
commonli
evalu
determin
mic
particular
antibiot
specif
bacteri
strain
figur
therefor
mic
report
gml
true
inhibitori
concentr
somewher
gml
gml
two
term
use
mic
lowest
concentr
inhibit
isol
test
mic
lowest
concentr
inhibit
isol
test
extrem
import
rememb
mic
vitro
characterist
antimicrobi
determin
strictli
adher
condit
environment
condit
site
infect
rare
correspond
vitro
suscept
test
condit
effect
element
oxygen
tension
ph
protein
bind
activ
antimicrobi
interest
need
consid
therefor
even
organ
appear
suscept
vitro
clinic
failur
may
occur
vivo
condit
detract
activ
drug
similarli
host
factor
may
actual
improv
vivo
activ
antimicrobi
macrophag
opson
factor
complement
may
act
synergist
antibiot
thu
provid
enhanc
antibacteri
activ
would
predict
vitro
addit
mani
bacteri
infect
resolv
spontan
without
use
antimicrobi
agent
mic
defin
amount
antimicrobi
necessari
inhibit
growth
microb
mbc
provid
inform
regard
concentr
drug
requir
kill
organ
mbc
like
mic
vitro
test
subject
similar
limit
relat
clinic
effect
mbc
calcul
determin
concentr
bacteria
incub
presenc
vari
drug
concentr
time
hour
defin
lowest
concentr
result
reduct
viabl
count
hour
compar
initi
inoculum
mbc
valu
gener
rang
doubl
dilut
higher
mic
valu
mic
better
standard
less
costli
less
labor
intens
use
often
mbc
howev
mbc
much
higher
mic
unless
drug
known
bacteriostat
organ
said
display
toler
antimicrobi
mic
mbc
commonli
util
describ
vitro
potenc
antimicrobi
agent
measur
account
pharmacokinet
properti
antimicrobi
agent
therefor
abil
predict
therapeut
efficaci
limit
pharmacokinet
ie
absorpt
distribut
metabol
excret
mani
antimicrobi
well
establish
howev
disciplin
pharmacodynam
recent
emerg
pharmacodynam
describ
relationship
drug
concentr
pharmacolog
effect
antibiot
describ
relationship
exist
drug
concentr
bacteria
expos
variou
site
infect
bacteri
kill
pharmacodynam
attempt
integr
microbiolog
pharmacokinet
data
clinic
relev
relationship
evolut
scienc
augment
bodi
knowledg
antimicrobi
best
treat
infect
addit
pharmacodynam
util
determin
impact
antimicrobi
resist
consider
pharmacodynam
help
defin
mic
limit
pharmacokinet
specif
antimicrobi
drug
would
expect
result
treatment
success
pharmacodynam
also
establish
ration
scientif
principl
provid
basi
develop
dose
strategi
optim
clinic
outcom
pharmacodynam
vivo
bacteri
kill
may
describ
function
durat
antimicrobi
drug
concentr
time
rel
mic
agent
particular
pathogen
product
pharmacokinet
paramet
drug
concentr
time
drug
exposur
bloodstream
dose
interv
express
auc
figur
outcom
infect
anim
model
human
studi
usual
correl
one
three
pharmacodynam
paramet
time
exposur
bacteria
concentr
antibiot
exceed
mic
agent
pathogen
time
mic
mic
ratio
peak
serum
concentr
antimicrobi
agent
mic
agent
pathogen
peak
antimicrobi
agent
thu
classifi
base
pharmacodynam
paramet
best
describ
vivo
pattern
bactericid
activ
tabl
antimicrobi
exhibit
timedepend
kill
agent
commonli
use
respiratori
tract
infect
exhibit
timedepend
kill
agent
kill
effici
concentr
exce
critic
valu
concentr
twoto
fourfold
higher
mic
gener
regard
optim
ie
greatest
likelihood
clinic
success
increas
drug
concentr
beyond
magnitud
improv
rate
extent
bacteri
kill
antibiot
exhibit
timedepend
kill
best
predictor
clinic
outcom
durat
time
concentr
site
infect
remain
mic
mic
bacteria
simplist
term
antibiot
need
highenough
concentr
longenough
period
time
site
infect
extracellular
pathogen
freedrug
concentr
serum
gener
proport
interstiti
fluid
bath
organ
proteinbound
drug
lack
antimicrobi
activ
therefor
proport
dose
interv
freedrug
concentr
serum
exce
antimicrobi
mic
pathogen
also
reflect
paramet
site
infect
amount
time
freedrug
concentr
timedepend
antibiot
remain
mic
mic
gener
vari
pathogen
immunocompet
host
data
vitro
pharmacokinet
simul
anim
model
human
clinic
studi
suggest
mic
need
achiev
bacteri
erad
gener
dose
interv
timedepend
antibiot
optim
pkpd
paramet
vari
somewhat
variabl
bacteri
kill
rate
exampl
mic
correl
optim
outcom
carbapenem
slightli
lower
penicillin
cephalosporin
carbapenem
rapid
bacteri
kill
effect
relationship
mic
efficaci
evalu
patient
acut
otiti
media
caus
pneumonia
h
influenza
bacteriolog
cure
rate
observ
mic
variou
dose
interv
moreov
hospit
patient
communityacquir
pneumonia
differ
clinic
outcom
observ
patient
receiv
cefuroxim
sodium
mg
per
day
continu
infus
mic
compar
mg
intermitt
three
time
daili
estim
mic
thu
serum
concentr
present
dose
interv
may
use
determin
suscept
limit
breakpoint
organ
given
dose
regimen
addit
proport
bacteria
therefor
suscept
base
proport
isol
mic
suscept
limit
breakpoint
antimicrobi
exhibit
timedepend
kill
moder
prolong
persist
effect
macrolidesazalid
macrolid
eg
erythromycin
clarithromycin
azalid
eg
azithromycin
exhibit
timedepend
kill
howev
prolong
postantibiot
effect
gramposit
cocci
h
influenza
pharmacodynam
paramet
agent
correl
efficaci
auc
mic
ratio
rather
mic
auc
mic
ratio
yield
maxim
efficaci
drug
macrolid
azalid
class
anim
model
approxim
concern
rais
regard
propens
azithromycin
select
bacteria
macrolideresist
impact
communitybas
azithromycin
use
carriag
resist
pneumonia
prospect
studi
singledos
azithromycin
mgkg
given
children
trachoma
chronic
diseas
caus
chlamydia
trachomati
household
contact
children
carriag
rate
azithromycinresist
pneumonia
immedi
treatment
week
month
month
treatment
respect
select
pressur
azithromycin
may
allow
growth
transmiss
preexist
azithromycinresist
strain
one
possibl
explan
observ
relat
long
serum
halflif
azithromycin
long
durat
subinhibitori
concentr
drug
serum
auc
two
antimicrobi
one
short
long
serum
halflif
compar
mic
valu
superimpos
period
window
potenti
darwinian
select
plot
figur
antimicrobi
short
halflif
durat
time
drug
concentr
fall
mic
total
elimin
bodi
rel
short
compar
antimicrobi
longer
halflif
antimicrobi
halflif
eg
azithromycin
total
elimin
bodi
occur
halfliv
day
period
subinhibitori
concentr
drug
may
pharmacodynam
explan
aforement
observ
concept
controversi
requir
valid
futur
studi
similar
find
recent
report
studi
israel
antimicrobi
exhibit
concentrationdepend
kill
prolong
persist
effect
fluoroquinolon
ketolid
exhibit
concentrationdepend
mechan
bacteri
kill
kill
effici
concentr
appreci
mic
pathogen
goal
dose
regimen
maxim
drug
concentr
site
infect
auc
mic
ratio
peak
mic
ratio
major
paramet
correl
efficaci
fluoroquinolon
erad
organ
best
level
higher
mic
pathogen
increas
time
mic
pneumonia
organ
rate
extent
kill
increas
rate
extent
kill
improv
organ
initi
suscept
quinolon
organ
rang
suscept
howev
rate
extent
kill
favor
potent
vitro
agent
optim
peaktom
ratio
obtain
bacteria
die
rapidli
consequ
period
time
bacteria
expos
drug
exposur
minim
although
peaktom
ratio
correl
optim
bactericid
activ
auc
mic
ratio
better
paramet
determin
efficaci
fluoroquinolon
moder
suscept
bacteria
pneumonia
fact
fluoroquinolon
dosefraction
studi
auc
mic
ratio
better
correl
efficaci
peak
mic
ratio
data
obtain
sever
sourc
includ
anim
model
sepsi
vitro
pharmacodynam
experi
clinic
outcom
studi
indic
magnitud
auc
mic
ratio
util
predict
outcom
forrest
et
al
demonstr
auc
mic
ratio
associ
highest
bacteri
erad
rate
treatment
infect
caus
gramneg
enter
pathogen
howev
gramposit
bacteria
appear
effect
auc
mic
ratio
appreci
lower
instanc
pneumonia
vitro
model
infect
demonstr
levofloxacin
ciprofloxacin
auc
mic
ratio
approxim
associ
reduct
bacteri
titer
ratio
associ
significantli
reduc
rate
bacteri
kill
instanc
bacteri
regrowth
similarli
lister
sander
report
levofloxacin
ciprofloxacin
auctom
ratio
associ
maxim
erad
pneumonia
vitro
model
infect
observ
support
data
nonneutropen
anim
model
infect
surviv
associ
auctom
ratio
pneumococcu
moreov
observ
vitro
model
infect
support
clinic
data
relationship
microbiolog
respons
auctom
ratio
gatifloxacin
levofloxacin
recent
evalu
patient
pneumococc
respiratori
tract
infect
analysi
demonstr
gatifloxacin
levofloxacin
auctom
ratio
least
correl
erad
pneumonia
auctom
ratio
associ
patient
posit
microbiolog
respons
therapi
patient
auctom
ratio
respons
therapi
probabl
attain
auctom
ratio
exceed
current
approv
dose
vari
among
fluoroquinolon
moxifloxacin
gatifloxacin
levofloxacin
ketolid
yet
approv
use
unit
state
optim
pkpd
paramet
yet
clearli
establish
certain
anim
model
infect
eg
mous
thigh
infect
suggest
auctom
ratio
correl
efficaci
pneumonia
ketolid
wherea
higher
ratio
improv
surviv
one
ketolid
telithromycin
auctom
ratio
correl
efficaci
pneumonia
may
much
higher
base
uncertainti
consid
telithromycin
consid
equival
current
avail
macrolidesazalid
subsequ
data
prove
otherwis
bacteriolog
erad
rate
clinic
trial
date
telithromycin
suggest
agent
may
valuabl
manag
communityacquir
respiratori
tract
infect
although
valu
studi
limit
bacteriolog
outcom
presum
outcom
base
clinic
outcom
pkpd
goal
identifi
use
anim
model
gener
correl
human
despit
pk
differ
anim
human
pd
target
similar
surpris
antimicrobi
target
within
bacteri
pathogen
mammalian
host
howev
anim
model
often
exclud
host
defens
ie
neutrophil
clearli
delin
effect
antimicrobi
therapi
data
suggest
pkpd
goal
may
lower
certain
agent
eg
ketolid
presenc
adequ
host
defens
furthermor
pkpd
goal
anim
model
calcul
base
assumpt
serum
concentr
approxim
concentr
site
infect
howev
certain
agent
eg
macrolid
tend
accumul
variou
site
infect
eg
epitheli
line
fluid
may
affect
pkpd
goal
agent
pharmacokinet
pharmacodynam
principl
play
import
role
evalu
select
antimicrobi
therapi
abr
bacteri
infect
gener
pkpd
paramet
best
predict
antimicrobi
activ
vivo
ie
mic
auc
mic
ratio
identifi
magnitud
pkpd
paramet
requir
efficaci
determin
ie
pkpd
goal
resist
defin
situat
pkpd
goal
achiev
pkpd
goal
gener
chang
base
site
infect
affect
dose
regimen
infect
pathogen
includ
resist
strain
use
agent
drug
class
long
freedrug
concentr
use
current
nccl
breakpoint
agent
vari
consider
depend
pathogen
wherea
pkpd
breakpoint
pathogen
pneumonia
pkpd
breakpoint
gener
within
onedoublingdilut
nccl
suscept
breakpoint
result
nccl
pkpd
breakpoint
similar
character
activ
variou
agent
pneumonia
howev
signific
differ
tween
nccl
pkpd
suscept
breakpoint
sever
antimicrobi
agent
h
influenza
breakpoint
use
nccl
vs
pkpd
affect
interpret
find
surveil
studi
pkpd
breakpoint
base
pkpd
relationship
agent
result
success
clinic
outcom
rather
mic
distribut
variou
speci
use
pkpd
breakpoint
overcom
limit
associ
use
nccl
breakpoint
previous
discuss
pharmacokineticpharmacodynam
pkpd
paramet
use
defin
suscept
breakpoint
antibiot
defin
suscept
breakpoint
antimicrobi
agent
requir
special
data
set
extens
vitro
clinic
studi
fact
case
pkpd
breakpoint
determin
previous
publish
data
ie
plasma
concentr
vs
time
curv
timedepend
agent
eg
pkpd
breakpoint
determin
identifi
timefram
xaxi
correspond
dose
interv
extrapol
concentr
yaxi
figur
similar
process
use
determin
pkpd
breakpoint
concentrationdepend
agent
auc
unbound
serum
fraction
divid
tabl
compar
suscept
isol
pneumonia
h
influenza
catarrhali
variou
antibiot
accord
pkpd
breakpoint
panel
use
pkpd
breakpoint
prefer
nccl
fda
breakpoint
allow
unbias
comparison
sinus
pathogen
use
one
breakpoint
agent
discuss
previou
section
two
import
factor
influenc
effect
particular
antibiot
regimen
drug
exposur
individu
reflect
pharmacokinet
pharmacodynam
drug
suscept
infect
pathogen
antiinfect
agent
select
determin
pkpd
breakpoint
time
mic
schemat
illustr
serum
pharmacokinet
profil
two
timedepend
oral
drug
regimen
dose
interv
drug
present
gml
dose
interv
drug
b
present
gml
approxim
dose
interv
gml
dose
interv
therefor
infect
caus
pathogen
mic
drug
gml
like
cure
drug
rather
drug
b
drug
b
would
howev
effect
strain
mic
gml
drug
b
present
gml
dose
interv
drug
b
two
differ
timedepend
drug
two
differ
dose
regimen
agent
similar
process
done
determin
pkpd
breakpoint
concentrationdepend
agent
auc
unbound
serum
fraction
divid
therapi
reflect
mic
agent
pathogen
howev
natur
differ
biolog
system
mic
human
pharmacokinet
curv
serum
distribut
across
rang
valu
consequ
bacteri
strain
less
suscept
antimicrobi
agent
other
suscept
other
similarli
peopl
absorb
metabol
distribut
excret
drug
rapidli
other
slowli
lead
consider
variat
pharmacokinet
paramet
result
variat
antimicrobialag
efficaci
vivo
may
differ
vitro
predict
drug
suscept
patient
determin
true
efficaci
agent
everi
patient
mic
caus
organ
agent
use
serum
pharmacokinet
agent
would
need
determin
patient
cours
physic
imposs
perform
small
scale
practic
activ
telithromycin
pneumonia
h
influenza
catarrhali
depend
pkpd
breakpoint
uncertain
time
activ
telithromycin
assum
similar
macrolidesazalid
inform
becom
avail
amoxclav
amoxicillinclavulan
na
applic
pd
pharmacodynam
pk
pharmacokinet
tmpsmx
trimethoprimsulfamethoxazol
valu
base
pkpd
breakpoint
except
pneumonia
valu
shown
pkpd
new
jan
nccl
breakpoint
clindamycin
tmpsmx
nccl
breakpoint
use
data
adapt
refer
highdos
amoxicillin
amoxicillinclavulan
defin
text
amoxicillin
compon
data
cefpodoxim
obtain
sentri
databas
mic
ciprofloxacin
isol
pneumonia
pkpd
breakpoint
therefor
ciprofloxacin
reliabl
cover
organ
tmp
compon
ethic
reason
pharmacokineticpharmacodynam
breakpoint
therefor
current
determin
mean
serum
pharmacokinet
valu
reflect
variat
pharmacokinet
patient
patient
patient
achiev
target
need
other
exceed
target
exampl
use
suscept
gatifloxacin
levofloxacin
pneumonia
shown
figur
suscept
breakpoint
standard
dose
regimen
agent
base
unbound
serum
auc
divid
gml
gatifloxacin
gml
levofloxacin
virtual
isol
suscept
breakpoint
figur
panel
b
howev
modal
mic
gatifloxacin
gml
one
quarter
breakpoint
wherea
levofloxacin
gml
one
half
breakpoint
variat
pharmacokinet
patient
therefor
like
result
levofloxacin
achiev
target
often
gatifloxacin
gatifloxacin
wider
safeti
margin
levofloxacin
mic
valu
breakpoint
variabl
pharmacokinet
agent
patient
enrol
clinic
trial
use
dose
regimen
mg
daili
gatifloxacin
mg
daili
levofloxacin
illustr
panel
c
figur
auc
valu
gatifloxacin
vari
mean
valu
levofloxacin
vari
mean
averag
auc
modal
mic
valu
two
agent
would
therefor
result
averag
auc
mic
ratio
gatifloxacin
levofloxacin
howev
variat
auc
patient
mic
isol
could
result
auc
mic
ratio
vari
gatifloxacin
levofloxacin
mont
carlo
simul
statist
method
estim
probabl
obtain
desir
target
case
pharmacokineticpharmacodynam
paramet
need
erad
infect
auc
mic
ratio
mont
carlo
method
randomli
select
valu
within
fix
rang
select
fit
probabl
distribut
eg
bell
curv
mont
carlo
simul
use
individu
valu
two
data
set
case
mic
auc
gener
random
auc
mic
ratio
randomli
chosen
mic
auc
valu
done
thousand
time
distribut
result
plot
result
simul
perform
time
data
panel
shown
panel
e
f
figur
base
analys
auc
mic
target
valu
achiev
certainti
gatifloxacin
levofloxacin
although
clinic
implic
find
yet
fulli
explor
analys
provid
insight
optim
patient
manag
fda
advisori
committe
antiinfect
drug
product
found
mont
carlo
simul
present
drusano
octob
reason
approach
address
issu
studi
problem
need
particularli
address
variat
pharmacokinet
dose
agent
cours
therapi
individu
patient
data
collect
date
reflect
pharmacokinet
determin
one
dose
interv
patient
oral
agent
respiratori
fluoroquinolon
greatest
vitro
activ
predomin
pathogen
howev
parenter
administ
ceftriaxon
may
assur
adequ
concentr
provid
better
bacteriolog
outcom
compar
oral
antimicrobi
therapi
rel
antimicrobi
activ
isol
pneumonia
base
pkpd
breakpoint
list
gatifloxacin
levofloxacin
moxifloxacin
ceftriaxon
highdos
amoxicillin
clavulan
extendedreleas
extra
strength
amoxicillin
clavulan
clindamycin
cefpodoxim
proxetil
cefuroxim
axetil
cefdinir
erythromycin
clarithromycin
azithromycin
telithromycin
cefprozil
tmpsmx
cefixim
loracarbef
cefaclor
rel
antimicrobi
activ
h
influenza
base
pkpd
breakpoint
gatifloxacin
moxifloxacin
ceftriaxon
cefixim
cefpodoxim
proxetil
extendedreleas
extra
strength
amoxicillinclavulan
amoxicillinclavulan
cefuroxim
axetil
cefdinir
tmpsmx
amoxicillin
cefprozil
cefaclor
loracarbef
doxycyclin
erythromycin
clarithromycin
azithromycin
telithromycin
rel
antimicrobi
activ
catarrhali
gatifloxacin
levofloxacin
moxifloxacin
cefixim
extendedreleas
extra
strength
amoxicillinclavulan
telithromycin
erythromycin
clarithromycin
azithromycin
doxycyclineceftriaxon
cefpodoxim
proxetil
cefdinir
cefuroxim
axetil
cefprozil
amoxicillin
tmpsmx
cefaclorloracarbef
current
oral
antimicrobi
class
use
treat
abr
includ
fluoroquinolon
macrolidesazalid
lincosamid
tetracyclin
sulfonamidestrimethoprim
one
ketolid
undergon
clinic
studi
yet
approv
clinic
use
fda
class
antimicrobialswhich
character
presenc
ringinclud
numer
compound
mani
differ
spectra
activ
exert
antibacteri
effect
inhibit
cellwal
synthesi
produc
autolysi
action
accomplish
bind
antimicrobi
variou
pbp
cell
wall
oral
avail
agent
includ
penicillin
without
compound
cephalosporin
cephalosporin
modifi
broaden
spectrum
antimicrobi
activ
increas
stabil
presenc
physicochem
properti
mani
oral
cephalosporin
make
less
suitabl
penicillinamoxicillin
pneumonia
infect
pathogen
cephalosporin
inher
less
activ
penicillin
amoxicillin
pneumoniaemani
agent
baselin
mic
fourfold
higher
amoxicillin
furthermor
cephalosporin
activ
absorb
gastrointestin
tract
limit
concentr
achiev
regardless
magnitud
dose
administ
amoxicillin
amoxicillinclavulan
less
potent
betterabsorb
deriv
ampicillin
amoxicillin
rel
safe
well
toler
given
intrins
activ
excel
bioavail
amoxicillin
gener
consid
activ
oral
streptococci
includ
pneumococci
addit
clavulan
amoxicillin
affect
intrins
activ
pneumonia
clavulan
preserv
activ
amoxicillin
presenc
resist
penicillin
isol
pneumonia
rel
may
overcom
use
higher
dose
amoxicillin
typic
adult
amoxicillin
dose
gday
typic
pediatr
amoxicillin
dose
mgkg
per
day
pharmacokinet
pharmacodynam
research
indic
higher
daili
dose
may
necessari
erad
pneumonia
high
mic
serum
level
amoxicillin
increas
linearli
dose
ie
gastrointestin
absorpt
limit
factor
differ
incid
advers
effect
lower
higher
dose
neglig
purpos
guidelin
highdos
amoxicillin
defin
gday
adult
mgkg
per
day
children
highdos
amoxicillinclavulan
defin
g
amoxicillin
mg
clavulan
per
day
adult
mgkg
per
day
amoxicillin
mgkg
per
day
clavulan
two
divid
dose
children
formul
highdos
amoxicillin
approv
fda
combin
clavulan
separ
formul
adult
children
adult
formul
use
modifiedreleas
mechan
provid
pharmacokinet
enhanc
version
amoxicillin
clavulan
pediatr
formul
provid
ratio
amoxicillin
clavulan
oral
suspens
highdos
amoxicillin
without
clavulan
appear
safe
promis
respiratori
tract
pathogen
includ
penicillinnonsuscept
pneumonia
organ
combin
clavulan
intrins
activ
amoxicillin
strain
h
influenza
fair
good
amoxicillin
time
less
potent
thirdgener
cephalosporin
ie
cefixim
cefpodoxim
occasion
failur
may
expect
infect
caus
strain
h
influenza
treat
standard
dose
amoxicillin
addit
clavulan
enhanc
activ
strain
h
influenza
drug
formul
optim
pkpd
perform
help
prevent
treatment
failur
occur
patient
concentr
drug
site
infect
vari
reason
less
averag
degre
especi
averag
tissu
concentr
close
mic
pathogen
see
discuss
mont
carlo
analys
reason
recent
studi
show
highdos
amoxicillin
clavulan
significantli
fewer
bacteriolog
failur
h
influenza
lower
dose
even
though
vitro
suscept
rate
regular
dose
amoxicillinclavulan
addit
clavulan
appear
drive
forc
develop
resist
administ
three
time
day
amoxicillinclavulan
associ
high
incid
gastrointestin
side
effect
compar
altern
incid
significantli
less
twiceaday
dose
gener
clavulan
dose
exce
approxim
mgkg
per
day
diarrhea
becom
problem
cefaclor
cefaclor
poor
activ
h
influenza
fair
activ
penicillinsuscept
pneumococci
activ
drsp
therefor
cefaclor
poor
overal
efficaci
bacteri
respiratori
tract
pathogen
cefdinir
cefdinir
extendedspectrum
semisynthet
cephalosporin
oral
administr
activ
pneumonia
compar
secondgener
agent
eg
cefuroxim
axetil
cefpodoxim
proxetil
activ
h
influenza
similar
cefuroxim
axetil
lower
cefpodoxim
proxetil
cefdinir
appreci
metabol
elimin
princip
via
renal
excret
agent
gener
well
toler
suspens
formul
well
accept
among
children
cefixim
prototyp
oral
thirdgener
oral
cephalosporin
cefixim
potent
activ
h
influenza
provid
limit
gramposit
coverag
includ
pneumonia
cefixim
activ
staphylococci
may
occasion
fail
even
penicillinsuscept
pneumococci
clinic
signific
activ
drsp
cefpodoxim
proxetil
cefpodoxim
proxetil
thirdgener
oral
cephalosporin
structur
analog
ceftriaxon
similar
activ
cefixim
respiratori
pathogen
activ
cefpodoxim
proxetil
similar
cefuroxim
axetil
cefdinir
pneumonia
greater
h
influenza
spectrum
activ
cefpodoxim
proxetil
often
regard
prefer
treatment
patient
treatment
highdos
amoxicillin
amoxicillinclavulan
fail
intoler
howev
clinic
util
ie
adher
suspens
formul
children
often
limit
poor
tast
cefprozil
cefprozil
anoth
goodtast
welltoler
broadspectrum
cephalosporin
activ
pneumonia
similar
cefdinir
cefuroxim
axetil
howev
cefprozil
markedli
less
activ
h
influenza
ceftriaxon
ceftriaxon
semisynthet
broadspectrum
cephalosporin
antibiot
intraven
iv
intramuscular
im
administr
ceftriaxon
sodium
complet
absorb
follow
im
administr
mean
maximum
plasma
concentr
occur
hour
post
dose
multipl
intraven
im
dose
rang
g
interv
result
accumul
ceftriaxon
singledos
valu
cefuroxim
axetil
parenter
cefuroxim
sodium
longestablish
histori
treatment
moderatetosever
lower
respiratori
infect
caus
h
influenza
pneumonia
oral
formul
cefuroxim
axetil
introduc
demonstr
good
potenc
efficaci
side
effect
profil
activ
cefuroxim
axetil
pneumonia
similar
cefpodoxim
cefdinir
cefuroxim
axetil
less
activ
cefpodoxim
h
influenza
loracarbef
loracarbef
compar
cefaclor
activ
pathogen
respiratori
tract
infect
fluoroquinolon
gatifloxacin
levofloxacin
moxifloxacin
fluoroquinolon
exert
bactericid
activ
bind
dna
gyras
topoisomeras
iv
imped
format
supercoil
dna
inhibit
relax
supercoil
dna
promot
doublestrand
dna
breakag
ciprofloxacin
excel
activ
h
influenza
catarrhali
auctom
ratio
pneumonia
wherea
target
auctom
ratio
fluoroquinolon
pneumonia
approxim
ciprofloxacin
combin
adequ
gramposit
therapi
eg
clindamycin
could
use
patient
rhinosinus
newer
fluoroquinolon
gatifloxacin
levofloxacin
moxifloxacin
remark
potenc
h
influenza
catarrhali
unlik
ciprofloxacin
potenc
gramposit
pathogen
includ
pneumonia
gemifloxacin
anoth
quinolon
activ
respiratori
pathogen
agent
current
approv
manag
sinus
gastrointestin
absorpt
agent
inhibit
coadministr
food
supplement
certain
multival
cation
magnesium
aluminium
iron
calcium
gener
lack
safeti
concern
ie
phototox
observ
quinolon
achil
tendon
ruptur
tendinopathi
like
class
effect
fluoroquinolon
particular
concern
among
patient
renal
dysfunctionfailur
use
gemifloxacin
women
longer
day
associ
increas
likelihood
rash
fluoroquinolon
current
approv
use
children
unit
state
predomin
concern
surround
fluoroquinolon
use
pertain
select
class
resist
organ
gramneg
especi
pseudomona
aeruginosa
staphylococci
pneumococci
recent
data
evalu
fluoroquinolon
propens
select
resist
pathogen
especi
pneumonia
suggest
differ
pharmacodynam
relat
frequenc
resist
select
specif
pharmacodynam
criteria
resist
prevent
still
establish
appear
potent
agent
least
like
promoteselect
resist
fluoroquinolon
increasingli
use
empir
therapi
manag
communityacquir
respiratori
tract
infect
part
preval
resist
tradit
agent
antimicrobi
agent
develop
resist
among
pneumonia
strain
one
fluoroquinolon
gener
lead
crossresist
member
fluoroquinolon
class
evid
inappropri
use
pharmacodynam
inferior
fluoroquinolon
link
develop
resist
clinic
failur
fluoroquinolon
use
indiscrimin
pharmacodynam
potent
fluoroquinolon
use
treat
suspect
pathogen
decis
made
use
fluoroquinolon
prefer
given
agent
like
achiev
optim
pkpd
paramet
rel
vitro
potenc
base
pkpd
paramet
sever
fluoroquinolon
moxifloxacin
gatifloxacin
levofloxacin
higher
dose
levofloxacin
mgday
improv
pkpd
profil
macrolidesazalid
erythromycin
clarithromycin
azithromycin
macrolid
includ
agent
erythromycin
clarithromycin
wherea
azithromycin
azalid
close
relat
agent
agent
activ
gramposit
gramneg
bacteria
bacteri
ribosom
consist
subunit
compris
rrna
subunit
approxim
protein
mechan
action
macrolidesazalid
involv
inhibit
rnadepend
protein
synthesi
bind
subunit
bacteri
ribosomespecif
polypeptid
exit
region
although
gener
consid
bacteriostat
bactericid
autolyt
speci
pneumococci
macrolid
exhibit
better
antibacteri
activ
environ
neutral
basic
ph
physicochem
characterist
due
fact
low
ph
macrolid
becom
posit
charg
readili
cross
biolog
membran
effect
pronounc
azithromycin
carri
doubleposit
charg
low
ph
macrolid
good
activ
macrolid
suscept
pneumococci
howev
increas
preval
macrolid
resist
pneumonia
associ
signific
likelihood
clinic
failur
furthermor
resist
macrolid
correl
increas
macrolid
use
agent
azithromycin
use
like
select
resist
strain
clarithromycin
use
clarithromycin
azithromycin
slightli
greater
activ
h
influenza
erythromycin
avail
erad
efficaci
studi
suggest
activ
similar
margin
higher
placebo
controversi
surround
antimicrobi
activ
metabolit
clarithromycin
intracellular
concentr
newer
agent
effect
ph
mic
result
none
impact
forego
conclus
activ
drug
extracellular
pathogen
ie
pneumonia
h
influenza
macrolidesazalid
activ
catarrhali
lincosamid
clindamycin
clindamycin
structur
differ
macrolid
also
act
bind
ribosom
subunit
suscept
bacteria
therebi
suppress
protein
synthesi
clindamycin
concentrationdepend
mechan
antimicrobi
activ
agent
use
clinic
treatment
suscept
gramposit
aerob
anaerob
well
mani
gramneg
anaerob
howev
activ
h
influenza
catarrhali
tetracyclin
doxycyclin
antibiot
inhibit
bacteri
growth
via
inhibit
rnadepend
protein
synthesi
revers
bind
ribosom
subunit
prevent
bind
trna
deriv
tetracyclin
doxycyclin
adequ
activ
penicillinsuscept
pneumococci
like
oral
likelihood
nonsuscept
doxycyclin
rise
pneumococc
strain
exhibit
degre
penicillin
resist
doxycyclin
also
activ
catarrhali
activ
h
influenza
limit
pharmacokinet
clinician
awar
possibl
photosensit
infrequ
esophag
caustic
burn
like
tetracyclin
usag
children
year
age
contraind
possibl
tooth
enamel
discolor
rifamycin
rifampin
prototyp
agent
class
rifampin
semisynthet
deriv
rifamycin
b
rifampin
bind
subunit
rna
polymeras
block
rna
transcript
suppress
initi
chain
format
result
bactericid
effect
rifampin
activ
varieti
intracellular
extracellular
microorgan
includ
gramposit
neg
bacteria
fungi
parasit
recent
surveil
studi
demonstr
rifampin
activ
approxim
pneumonia
h
influenza
catarrhali
isol
respect
rifampin
avail
decad
pkpd
profil
agent
known
despit
activ
predomin
respiratori
pathogen
rifampin
use
indiscrimin
monotherapi
prolong
durat
resist
agent
develop
rapidli
usual
dose
antimicrobi
effect
rifampin
rel
specif
microorgan
ie
mammalian
rna
synthesi
affect
rifampin
distribut
wide
throughout
bodi
wellknown
induc
sever
cytochrom
isoenzym
therefor
high
potenti
drug
interact
folat
inhibitor
trimethoprimsulfamethoxazol
sulfonamid
disrupt
bacteri
folic
acid
synthesi
inhibit
dihydroptero
synthas
result
bacteriostat
activ
tmp
pyrimidin
analog
inhibit
dihydrofol
reductas
sulfonamid
trimethoprim
block
folic
acid
synthesi
differ
site
potenti
antimicrobi
activ
produc
synergist
activ
high
rate
resist
drug
present
pneumococci
h
influenza
catarrhali
intrins
resist
trimethoprim
addit
agent
caus
skin
rash
erythema
multiform
toxic
epiderm
necrolysi
potenti
fatal
new
antibiot
ketolid
new
class
semisynthet
antibiot
close
relat
macrolid
design
theoret
provid
greater
activ
respiratori
tract
pathogen
particularli
macrolideresist
strain
pneumonia
mechan
action
ketolid
similar
macrolid
howev
ketolid
higher
affin
target
bind
site
rrna
ribosom
subunit
partli
respons
greater
vitro
activ
respiratori
tract
pathogen
ketolid
concentrationdepend
mechan
antimicrobi
kill
structur
modif
induc
ribosom
methylasemedi
resist
among
pneumococc
strain
erm
determin
common
macrolid
azalid
furthermor
ketolid
may
retain
activ
strain
ribosom
methylasemedi
effluxmedi
resist
mechan
present
and
et
al
evalu
impact
neutrophil
bacteriostat
activ
telithromycin
pneumonia
murin
thigh
model
report
enhanc
potenc
increas
ketolid
presenc
neutrophil
tessier
et
al
studi
pneumococc
isol
murin
thigh
infect
model
observ
telithromycin
aucmic
ratio
approxim
correl
bacteriostat
activ
wherea
ratio
need
obtain
bactericid
activ
compound
model
drusano
preston
evalu
pharmacodynam
profil
telithromycin
mg
daili
patient
communityacquir
pneumonia
clinic
studi
involv
infect
patient
microbiolog
clinic
outcom
correl
aucmic
ratio
author
report
aucmic
ratio
result
erad
presum
erad
infect
pathogen
time
write
research
need
determin
aucmic
ratio
patient
communityacquir
pneumonia
relev
sinus
macrolid
azalid
ketolid
limit
activ
h
influenza
due
efflux
pump
oxazolidinon
new
class
antibiot
uniqu
mechan
action
protein
synthesi
inhibit
gramposit
pathogen
linezolid
prototyp
agent
class
current
approv
complic
infect
emerg
linezolidresist
gramposit
cocci
report
glycylcyclin
advancedgener
tetracyclin
deriv
design
overcom
mechan
resist
class
antibiot
agent
class
still
clinic
develop
time
write
evid
control
clinic
trial
repres
optim
basi
recommend
antimicrobi
therapi
abr
howev
mani
current
clinic
trial
evalu
antimicrobi
therapi
methodolog
limit
eg
diagnost
criteria
compar
endpoint
outcom
measur
preclud
consid
evid
furthermor
trend
antimicrobi
resist
chang
dramat
past
year
affect
applic
evid
older
clinic
trial
larg
metaanalysi
recent
conduct
evalu
role
antimicrobi
therapi
gener
role
specif
agent
class
abr
mani
individu
trial
conduct
prior
widespread
resist
current
report
pneumonia
h
influenza
result
find
metaanalysi
may
applic
current
treatment
abr
methodolog
use
present
guidelin
evalu
antimicrobi
therapi
abr
howev
take
account
current
high
level
antibioticresist
organ
absenc
current
evid
becom
challeng
identifi
optim
therapi
abr
rather
subject
compil
rank
order
antimicrobi
agent
base
vitro
activ
data
expert
consensu
util
object
methodolog
assess
treatment
option
approach
involv
use
mathemat
modelth
pool
therapeut
outcom
modelto
predict
treatment
outcom
abr
therapeut
outcom
model
extrapol
work
origin
conduct
marchant
et
al
involv
correl
vivo
potenc
variou
antimicrobi
agent
clinic
outcom
use
doubletympanocentesi
methodolog
otiti
media
studi
marchant
et
al
observ
nonbacteri
factor
result
discrep
bacteriolog
clinic
outcom
exampl
agent
bacteriolog
cure
rate
necessarili
clinic
cure
rate
patient
continu
experi
symptom
sult
nonbacteri
factor
eg
viral
infect
persist
middl
ear
effus
convers
antimicrobi
agent
rel
poor
bacteriolog
cure
rate
often
appear
effect
expect
high
rate
spontan
resolut
symptom
result
highli
efficaci
agent
gener
slightli
better
impact
clinic
outcom
ie
symptom
compar
lessefficaci
agent
despit
dramat
differ
bacteriolog
outcom
therapeut
outcom
model
tool
help
predict
likelihood
bacteriolog
success
particular
antimicrobi
agent
account
variou
factor
includ
proport
patient
clinic
diagnosi
acut
bacteri
rhinosinus
posit
sinu
aspir
clinic
resolut
diseas
cultureneg
patient
group
distribut
pathogen
frequent
encount
abr
spontan
resolut
rate
associ
pathogen
vitro
suscept
predomin
sinus
pathogen
antimicrobi
agent
pkpd
breakpoint
figur
therapeut
outcom
model
also
predict
overal
clinic
outcom
total
patient
group
ie
either
bacteri
nonbacteri
diseas
first
compon
mathemat
model
involv
process
account
nonbacteri
diseas
among
patient
nasalsinu
symptom
undergo
sinu
tap
approxim
neg
bacteri
cultur
symptom
usual
due
primari
viral
process
major
patient
achiev
complet
resolut
symptom
without
antibiot
therapi
addit
patient
persist
nasalsinu
symptom
regardless
antibiot
therapi
prescrib
persist
symptom
like
due
nonbacteri
caus
facial
pain
nasal
obstruct
rhinorrhea
eg
allergi
headach
anatom
factor
next
compon
account
distribut
pathogen
abr
likelihood
spontan
resolut
associ
pathogen
base
placebocontrol
trial
acut
otiti
media
among
bacteri
infectionsa
mention
aboveth
pathogen
distribut
adult
pneumonia
h
influenza
catarrhali
studi
suggest
bacteri
sinu
infect
caus
pathogen
pneumonia
h
influenza
catarrhali
model
percentag
use
pathogen
distribut
modifi
yield
total
also
miscellan
pathogen
omit
model
guidelin
revis
fda
typic
consid
import
pathogen
adequ
suscept
data
pathogen
lack
activ
given
antimicrobi
agent
miscellan
pathogen
like
close
averag
activ
three
usual
pathogen
overal
suscept
pattern
given
agent
substanti
affect
exclus
miscellan
pathogen
pathogen
distribut
children
pneumonia
h
influenza
catarrhali
modif
valu
made
model
give
total
spontan
resolut
rate
use
model
pneumonia
h
influenza
catarrhali
pathogen
spontan
resolut
rate
vari
depend
durat
clinic
observ
age
statu
mucos
health
base
valu
spontan
resolut
symptom
would
expect
adult
document
bacteri
infect
total
clinic
diagnos
patient
group
among
untreat
children
spontan
resolut
symptom
would
expect
among
bacteri
infect
clinic
defin
pediatr
sinus
group
model
also
account
effect
antimicrobi
therapi
achiev
clinic
outcom
use
current
suscept
data
organ
pkpd
breakpoint
pkpd
suscept
breakpoint
given
dose
regimen
shown
correl
bacteriolog
cure
rate
resolut
rate
bacteri
infect
group
total
patient
group
shown
marchant
plot
figur
data
set
use
complet
mic
distribut
avail
proport
isol
inhibit
pkpd
breakpoint
could
determin
outcom
calcul
shown
marchant
plot
show
predict
bact
riolog
outcom
bacteri
infect
group
total
patient
group
marchant
plot
rel
rank
order
data
use
surveil
data
may
therefor
alter
rel
rank
order
resolut
rate
base
vitro
microbiolog
efficaci
guarante
clinic
outcom
howev
absenc
evid
therapeut
outcom
model
use
regard
best
method
avail
object
predict
clinic
outcom
detail
descript
therapeut
outcom
model
provid
elsewher
supplement
recommend
base
therapeut
outcom
model
describ
tabl
summar
panel
antimicrobi
treatment
guidelin
adult
children
respect
multipl
factor
play
role
antimicrobi
select
process
seriou
intracrani
extrasinu
complic
associ
abr
usual
aris
secondari
pneumonia
infect
import
initi
therapi
adequ
cover
pneumonia
gramneg
coverag
h
influenza
catarrhali
children
ignor
howev
ration
approach
treatment
abr
consid
aforement
concern
along
logic
applic
microbiolog
pharmacodynamicpharmacokinet
principl
panel
guidelin
adult
children
abr
character
two
group
patient
mild
diseas
receiv
antibiot
within
previou
week
mild
diseas
receiv
antibiot
within
prior
week
moder
diseas
regardless
recent
antibiot
exposur
mention
previous
primari
reason
antimicrobi
therapi
recommend
abr
improv
patient
health
term
mild
moder
integr
decisionmak
process
reflect
degre
pa
tient
discomfort
evidenc
symptom
complex
time
cours
diseas
likelihood
experienc
spontan
resolut
symptom
word
patient
moder
diseas
like
requir
therapeut
intervent
achiev
resolut
symptom
patient
less
like
toler
treatment
failur
differ
diseas
sever
impli
presenc
absenc
antimicrobi
resist
patient
howev
may
alway
neatli
categor
base
classif
evalu
diseas
sever
requir
clinic
judgment
gain
clinician
familiar
patient
sever
lifethreaten
infect
without
complic
address
guidelin
recent
antibiot
use
major
risk
factor
associ
infect
caus
resist
pathogen
risk
factor
includ
age
year
attend
daycar
center
recent
antimicrobi
exposur
increas
risk
carriag
infect
due
resist
organ
antimicrobi
therapi
base
patient
histori
recent
antibiot
use
panel
guidelin
stratifi
patient
accord
antibiot
exposur
within
previou
week
lack
respons
therapi
hour
arbitrari
timefram
establish
defin
treatment
failur
clinician
monitor
patient
respons
antibiot
therapi
may
includ
instruct
patient
call
offic
clinic
persist
worsen
symptom
next
day
current
recommend
durat
antimicrobi
treatment
abr
day
base
result
clinic
trial
perform
preand
posttreat
sinu
aspir
new
techniqu
serial
sinu
sampl
design
better
defin
optim
durat
treatment
abr
allergi
antibiot
ie
age
limit
certain
antimicrobi
ie
fluoroquinolon
may
preclud
use
optim
antimicrobi
clinician
awar
potenti
treatment
failur
situat
panel
use
therapeut
outcom
model
tool
develop
antimicrobi
recommend
recent
best
data
use
model
panel
realiz
resist
rate
may
chang
time
may
vari
commun
commun
panel
therefor
continu
revis
guidelin
resist
rate
chang
new
antibiot
introduc
respiratori
quinolon
ie
gatifloxacin
levofloxacin
moxifloxacin
activ
telithromycin
pneumonia
h
influenza
catarrhali
depend
pkpd
breakpoint
uncertain
time
activ
telithromycin
assum
similar
macrolidesazalid
inform
becom
avail
otolaryngologyhead
neck
surgeri
sinu
allergi
health
partnership
januari
follow
valu
calcul
use
therapeut
outcom
model
repres
predict
clinic
outcom
clinic
diagnos
sinus
clinic
criteria
use
place
bacteriolog
criteria
ie
bacteriolog
outcom
patient
bacteri
infect
clinic
outcom
consist
encount
everyday
practic
predict
bacteriolog
outcom
patient
bacteri
infect
may
ideal
valu
obtain
use
therapeut
outcom
model
may
inconsist
clinic
experi
mention
previous
antibiot
reserv
patient
bacteri
infect
primari
goal
erad
pathogen
site
infect
howev
limit
associ
differenti
bacteri
nonbacteri
diseas
inevit
result
patient
nonbacteri
diseas
receiv
antibiot
therapi
use
antibiot
patient
nonbacteri
diseas
often
dilut
reduc
perceiv
bacteriolog
efficaci
antibiot
often
case
bacteriolog
find
clinic
trial
methodolog
limit
eg
inclus
criteria
diagnost
criteria
accord
therapeut
outcom
model
antibiot
place
follow
rel
rank
order
predict
clinic
efficaci
adult
patient
respiratori
quinolon
gatifloxacin
levofloxacin
moxifloxacin
ceftriaxon
amoxicillinclavulan
mg
per
day
amoxicillinclavulan
mg
per
day
highdos
amoxicillin
gday
amoxicillin
gday
cefpodoxim
proxetil
cefixim
base
h
influenza
catarrhali
coverag
cefuroxim
axetil
cefdinir
tmpsmx
doxycyclin
clindamycin
base
gramposit
coverag
cefprozil
azithromycin
clarithromycin
erythromycin
telithromycin
cefaclor
loracarbef
predict
spontan
resolut
rate
clinic
diagnos
sinus
untreat
adult
abr
accord
pool
therapeut
outcom
model
antibiot
place
follow
rel
rank
order
predict
clinic
efficaci
children
ceftriaxon
highdos
amoxicillinclavulan
mg
per
kg
per
day
amoxicillinclavulan
mg
per
kg
per
day
highdos
amoxicillin
mgkg
per
day
amoxicillin
mgkg
per
day
cefpodoxim
proxetil
cefixim
base
h
influenza
catarrhali
coverag
cefuroxim
axetil
cefdinir
tmpsmx
clindamycin
base
gramposit
coverag
cefprozil
azithromycin
clarithro
activ
telithromycin
pneumonia
h
influenza
catarrhali
depend
pkpd
profil
uncertain
time
activ
telithromycin
assum
similar
macrolidesazalid
inform
becom
avail
otolaryngologyhead
neck
surgeri
volum
number
sinu
allergi
health
partnership
mycin
erythromycin
cefaclor
loracarbef
predict
spontan
resolut
rate
untreat
children
abr
recommend
patient
improv
worsen
hour
treatment
provid
base
spectrum
activ
initi
therapi
major
sinus
pathogen
estim
likelihood
particular
pathogen
encount
patient
failur
type
initi
therapi
util
lieu
obtain
cultur
guid
switch
therapi
hour
recommend
select
antimicrobi
therapi
current
guidelin
focus
compar
previou
guidelin
decis
recommend
fewer
antimicrobi
option
particularli
patient
moder
diseas
base
evalu
antimicrobi
efficaci
tabl
recommend
initi
therapi
adult
patient
mild
diseas
receiv
antibiot
previou
week
includ
follow
choic
amoxicillin
clavulan
mg
per
day
amoxicillin
gday
cefpodoxim
proxetil
cefuroxim
axetil
cefdinir
tmpsmx
doxycyclin
azithromycin
clarithromycin
erythromycin
telithromycin
may
consid
patient
allergi
bacteriolog
failur
rate
possibl
failur
respond
antimicrobi
therapi
hour
prompt
either
switch
altern
antimicrobi
therapi
reevalu
patient
see
tabl
chang
antibiot
therapi
made
clinician
consid
limit
coverag
initi
agent
recommend
initi
therapi
adult
mild
diseas
receiv
antibiot
previou
week
adult
moder
diseas
includ
follow
choic
respiratori
fluoroquinolon
gatifloxacin
levofloxacin
moxifloxacin
highdos
amoxicillinclavulan
mg
per
day
widespread
use
respiratori
fluoroquinolon
patient
milder
diseas
may
promot
resist
especi
gut
organ
class
agent
ceftriaxon
combin
therapi
adequ
gramposit
neg
coverag
may
also
consid
exampl
appropri
regimen
combin
therapi
includ
highdos
amoxicillin
clindamycin
plu
cefixim
highdos
amoxicillin
clindamycin
plu
rifampin
ceftriaxon
select
dose
gday
im
iv
use
day
durat
therapi
arbitrarili
extrapol
committe
base
data
acut
otiti
media
studi
rifampin
use
monotherapi
casual
longer
day
resist
emerg
rapidli
agent
failur
respond
antimicrobi
therapi
hour
prompt
either
switch
altern
antimicrobi
therapi
reevalu
patient
see
tabl
chang
antibiot
therapi
made
clinician
consid
limit
coverag
initi
agent
patient
receiv
effect
antibiot
therapi
continu
symptomat
need
evalu
ct
scan
fiberopt
endoscopi
sinu
aspir
cultur
may
necessari
amoxicillin
clavulan
select
patient
risk
infect
penicillinresist
pneumonia
drsp
eg
recent
antimicrobi
use
immunodefici
frequent
exposur
children
attend
day
care
etc
highdos
regimen
ie
mg
use
recommend
pediatr
patient
see
tabl
recommend
initi
therapi
children
mild
diseas
receiv
antibiot
previou
week
includ
follow
highdos
amoxicillinclavulan
mg
per
kg
per
day
highdos
amoxicillin
mgkg
per
day
cefpodoxim
proxetil
cefuroxim
axetil
cefdinir
tmpsmx
azithromycin
clarithromycin
erythromycin
recommend
patient
histori
immedi
type
hypersensit
reaction
antibiot
limit
effect
major
pathogen
abr
bacteri
failur
possibl
clinician
differenti
immedi
hypersensit
reaction
less
danger
side
effect
children
immedi
hypersensit
reaction
may
need
desensit
sinu
cultur
ancillari
procedur
studi
children
type
reaction
side
effect
may
toler
one
specif
anoth
chang
antibiot
therapi
made
clinician
consid
limit
coverag
initi
antibiot
respiratori
fluoroquinolon
gatifloxacin
levofloxacin
moxifloxacin
ceftriaxon
amoxicillinclavulan
mg
current
best
coverag
pneumonia
h
influenza
term
mild
moder
design
aid
select
antibiot
therapi
differ
sever
diseas
impli
presenc
absenc
antimicrobi
resist
rather
terminolog
indic
rel
degre
accept
possibl
therapeut
failur
likelihood
achiev
spontan
resolut
symptom
determin
diseas
sever
lie
clinician
evalu
patient
histori
clinic
present
sever
lifethreaten
infect
without
complic
address
guidelin
antibiot
therapi
within
week
risk
factor
infect
resist
organ
antibiot
choic
base
risk
factor
total
daili
dose
amoxicillin
amoxicillin
compon
amoxicillinclavulan
vari
gday
lower
daili
dose
gday
appropri
mild
diseas
patient
risk
factor
infect
resist
pathogen
includ
recent
antibiot
use
higher
daili
dose
gday
may
advantag
area
high
preval
penicillinresist
pneumonia
drsp
patient
moder
diseas
patient
may
need
better
h
influenza
coverag
patient
risk
factor
infect
resist
pathogen
greater
potenti
treatment
failur
resist
pathogen
patient
group
vitro
spectrum
activ
combin
therapi
use
appropri
gramposit
neg
coverag
may
appropri
exampl
combin
therapi
regimen
includ
highdos
amoxicillin
gday
clindamycin
plu
cefixim
highdos
amoxicillin
gday
clindamycin
plu
rifampin
clinic
evid
time
howev
safeti
efficaci
combin
cephalosporin
consid
initi
patient
penicillin
intolerancenontyp
hypersensit
reaction
eg
rash
tmpsmx
doxycyclin
macrolid
azalid
ketolid
recommend
unless
patient
allerg
effect
major
pathogen
abr
limit
bacteri
failur
possibl
respiratori
fluoroquinolon
eg
gatifloxacin
levofloxacin
moxifloxacin
recommend
patient
allergi
recent
fail
regimen
telithromycin
approv
use
fda
time
write
necessari
antibiot
recommend
initi
therapi
provid
excel
activ
predomin
abr
pathogen
includ
pneumonia
h
influenza
addit
histori
physic
examin
cultur
andor
ct
scan
may
indic
possibl
less
common
pathogen
consid
wellknown
induc
sever
cytochrom
isoenzym
therefor
high
potenti
drug
interact
